ClinicalTrials.gg
RecruitingNCT04221035HR-NBL2Updated Jun 26, 2025

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

A Phase 3 interventional study of Vincristine and Carboplatin in High-Risk Neuroblastoma and Patient With Insufficient Response Chemoimmunotherapy, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 142 sites in 20 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing vincristine in Neuroblastoma — 3 open to participants now, 4 under way, 2 of them phase 3. Vincristine · Neuroblastoma.

Planned enrollment
2nd of 16
800 · median 44
Started
2019
the only one that year
Phase 3
3 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Gustave Roussy, Cancer Campus, Grand Paris

Among the 16 studies testing vincristine in Neuroblastoma, this one is the 2nd largest by planned enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 14th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

3 of the 16 studies testing vincristine in Neuroblastoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About vincristine

Vincristine: first FDA approval 1963 (ONCOVIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vincristine in Neuroblastoma, or all of them as a file.
02

Study summary

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

Read the detailed description

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

The first randomization (R-I) will compare the efficacy of two induction chemotherapies (RAPID COJEC and GPOH regimens) in a phase III setting. The primary endpoint will be the 3-year EFS from date of randomization . The R-I randomization will be stratified on age, stage, MYCN status and countries.

The second randomization (R-HDC) will compare the efficacy of single HDC with Bu-Mel versus tandem HDC with Thiotepa followed by Bu-Mel. The primary endpoint is 3-year EFS calculated from the date of the R-HDC randomization. The R-HDC randomization will be stratified on the age, stage, MYCN status, induction chemotherapy regimen, response to induction phase and countries.

The impact of local treatment in this phase III setting will be assessed, according to the presence or not of a macroscopic residual disease after surgery and HDC.

In case of macroscopic residual disease, 21.6 Gy radiotherapy to the preoperative tumor bed will be randomized (R-RTx) versus the same treatment plus a sequential boost of additional 14.4 Gy to the residual tumor. The primary endpoint of R-RTx is 3-year EFS from the date of the R-RTx randomization. The R-RTx randomization will be stratified on age, stage, MYCN status, induction chemotherapy regimen, HDC regimen and countries.

In case of no macroscopic residual disease, 21.6 Gy radiotherapy will be delivered to the preoperative tumor bed.

03

Conditions studied

  • High-Risk Neuroblastoma
  • Patient With Insufficient Response Chemoimmunotherapy

Browse trials for

04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Enrollment in HR-NBL2 will be performed:

  • at diagnosis before the beginning of chemotherapy or
  • up to 21 days after one course of Carboplatin-Etoposide for patients with localized neuroblastoma or infants with neuroblastoma with MYCN amplification or patients with metastatic neuroblastoma treated in emergency or
  • up to 21 days after one course of the current protocol for R-I randomisation (RAPID COJEC/GPOH) low/intermediate risk neuroblastoma in Germany/Netherlands for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification

HR-NBL2 eligibility criteria:

  1. Established diagnosis of neuroblastoma according to the SIOPEN- modified International Neuroblastoma Risk Group (INRG) criteria, High-risk neuroblastoma defined as:

    • Stage M neuroblastoma above 365 days of age at diagnosis (no upper age limit) and Ms neuroblastoma 12-18 months old, any MYCN status or
    • L2, M or Ms neuroblastoma any age with MYCN amplification, or focal high level MYC or MYCL amplification.

    In Germany, patients aged less than 18 months with stage M and without MYCN amplification will not be enrolled in HR-NBL2 trial.

  2. No previous chemotherapy or up to 21 days after one cycle of Carboplatin-Etoposide chemotherapy for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification or patients with metastatic neuroblastoma treated in emergency or up to 21 days after one course of the current protocol for low/intermediate risk neuroblastoma in Germany/Netherlands for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification
  3. Females of must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment. Sexually active patients must agree to use acceptable and appropriate while on HR-NBL2 study and for one year after stopping the study. Acceptable contraception is defined in CTFG Guidelines "Recommendations related to contraception and pregnancy testing in clinical trials" (Appendix 11). Female patients who are lactating must agree to stop breast-feeding.
  4. Written to enter the HR-NBL2 protocol from patient or parents/legal representative, patient, and age-appropriate assent.
  5. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
  6. Patients should be able and willing to comply with study visits and procedures as per protocol

R-I eligibility criteria:

- Written informed consent to enter the R-I randomisation from patient or parents/legal representative, patient, and age- appropriate assent.

In case of parents'/patient's refusal to R-I, or Organ toxicity exclusion criteria at diagnosis, patients can still be enrolled in HR- NBL2 trial with parents'/patient's consent before or within 3 weeks from the beginning of chemotherapy

R-HDC randomisation (Single HDC Bu-Mel/ Tandem HDC Thiotepa+Bu-Mel) Etoposide or one course of the current protocol for low/intermediate risk neuroblastoma in Germany/Netherlands). Patients will be treated with the standard induction regimen per country (Rapid COJEC or GPOH) and will be potentially eligible for subsequent randomisations.

Randomisation for HDC strategy will be performed at the end of induction after the disease evaluation and after surgery of the primary tumour for those patients who will receive surgery before HDC.

R-HDC eligibility criteria:

  1. - Stage M neuroblastoma above 365 days of age at diagnosis, any MYCN status, EXCEPT patients with stage M or Ms 12-18 months old with numerical chromosomal alterations only, and in complete metastatic response at the end of induction: in this case, patients will have surgery and no further treatment.

    OR

    - L2, M or Ms neuroblastoma, any age, with MYCN amplification, or focal high level MYC or MYCL amplification

  2. Age \< 21 years at the time of randomization
  3. Complete response (CR) or partial response (PR) at metastatic sites:

    • Bone disease: mIBG uptake completely resolved or SIOPEN score ≤ 3 and at least 50% reduction in mIBG score (or ≤ 3 bone lesions and at least 50% reduction in number of FDG- PET-avid bone lesions for mIBG-nonavid tumours).
    • Bone marrow disease: CR and/or minimal disease (MD) according to International Neuroblastoma Response Criteria
    • Other metastatic sites: CR. (after induction chemotherapy +/- surgery), except for distant lymph nodes for which PR is accepted with a possible secondary surgery
  4. Acceptable organ function and performance status:

    • Performance status ≥ 50%.
    • Hematological status: >0.5x109/L, > 20x 109/L
    • Cardiac function: (\< grade 2)
    • Normal chest X-Ray and oxygen saturation.
    • Absence of any toxicity ≥ grade 3. 4) Sufficient collected stem cells available; a total harvest of at least 6 x 106/kg CD34+ cells, to be stored in at least 4 separate bags to administer at least 3 x 106/kg CD34+ cells per rescue.
  5. Written informed consent, including agreement of patient or parents/legal guardian for minors, to enter the R-HDC randomisation.
  6. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
  7. Patients should be able and willing to comply with study visits and procedures as per protocol.

In case of parents'/patient's refusal, or insufficient stem cells, collection for tandem HDC but with a minimum of 3 x 106 CD34+ cells/kg body weight, or in case of patients older than 21 years, or organ toxicity, HDC will consist on the standard HD Bu-Mel and patients will be eligible for the subsequent randomisation.

R-RTx randomisation (Local Radiotherapy) Chemoimmunotherapy arm

R-RTx eligibility criteria:

An evaluation of the local disease will be performed after HDC/ASCR and surgery:

  • In case of no local macroscopic disease, all patients will receive 21,6-Gy radiotherapy to the pre-operative tumour bed
  • In case of local macroscopic residual disease, patients will be eligible to R-RTx if the following criteria are met:

    1. No evidence of disease progression after HDC/ASCR.
    2. Interval between the last ASCR and radiotherapy start between 60 and 90 days.
    3. Performance status greater or equal 50%.
    4. Hematological status: ANC >0.5x109/L, platelets > 20x109/L.
    5. Written informed consent, including agreement of patient or parents/legal guardian for minors, to enter the R-RTx randomisation.
    6. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
    7. Patients should be able and willing to comply with study visits and procedures as per protocol.

In case of parents'/patient's refusal of the randomisation, the patient will receive 21.6 Gy radiotherapy to the pre-operative tumour bed.

Chemoimmunotherapy arm eligibility criteria:

  1. Insufficient metastatic response at the end of induction chemotherapy, defined as:

    • SIOPEN score > 3 or less than 50% reduction in mIBG score (or > 3 bone lesions or less 50% reduction in number of FDG-PET-avid bone lesions for mIBG-non avid tumours) OR
    • Bone marrow disease: SD according to International Neuroblastoma Response Criteria OR
    • Other metastatic sites: PR or SD. For distant lymph nodes: PR and not resectable or SD.
  2. Performance status ≥ 50%.
  3. Hematological status: ANC>0.75x109/L without G-CSF for at least 48 hours (or ANC ≥ 0.50 x 109 /L in case of bone marrow involvement), platelets > 50x 109/L and rising, without platelets transfusion for 72 hours.
  4. or ALT ≤7.5 and total ≤1.5 ULN. In patients with liver metastases, total bilirubin ≤2.5 ULN is allowed.
  5. No active infection;
  6. No grade >2 gastrointestinal toxicity.
  7. No grade ≥ 3 toxicity related to previous treatment.
  8. Oxygen saturation > 94%

Non-inclusion criteria for HR-NBL2:

  1. Any negative answer concerning the HR-NLB2 inclusion criteria
  2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving his consent.
  3. Participating in another clinical study with an IMP while on study treatment.
  4. Chronic inflammatory bowel disease and/or bowel obstruction.
  5. Pregnant or breastfeeding women.
  6. Known to the active substance or to any of the of the study drugs
  7. Concomitant self-medication medicine that in the investigator opinion could interact with study treatments, including herbal medicine (e.g. St John's Wort (Hypericum Perforatum).

Non-inclusion criteria specific to the R-I randomisation (RAPID COJEC/GPOH):

  1. Urinary tract obstruction ≥ grade 3
  2. Heart failure or myocarditis ≥ grade 2, any arrhythmia or myocardial infection
  3. Peripheral motor or sensory neuropathy ≥ grade 3
  4. Demyelinating form of Charcot-Marie-Tooth syndrome
  5. Hearing impairment ≥ grade 2
  6. Concurrent prophylactic use of phenytoin
  7. Cardiorespiratory disease that contraindicates hyperhydration

Non-inclusion criteria common to all randomisations (R-I, R-HDC, and R-RTx):

  1. Any negative answer concerning the inclusion criteria of R-I or R- HDC or R-RTx will render the patient ineligible for the corresponding therapy phase randomisation. However, these patients may remain on study and be considered to receive standard treatment of the respective therapy phase, and may be potentially eligible for subsequent randomisations.
  2. Liver function: Alanine aminotransferase (ALT) > 3.0 x ULN and blood bilirubin > 1.5 x ULN (toxicity ≥ grade 2). In case of toxicity ≥ grade 2, call national principal investigator study coordinator to discuss the feasibility.
  3. Renal function: and/or \< 60 ml/min/1.73m² (toxicity ≥ grade 2). If GFR \< 60ml/min/1.73m², call national principal investigator study coordinator to discuss about the treatment.
  4. Dyspnea at rest and/or pulse oximetry \<95% in air (only for R-HDC, and R-RTx)
  5. Any uncontrolled intercurrent illness or infection that in the investigator opinion would impair study participation.
  6. Concomitant use with yellow fever vaccine and with live virus or bacterial vaccines.
  7. Patient allergic to peanut or soya.

Non-inclusion criteria to R-HDC:

- Any negative answer concerning the R-HDC inclusion criteria

Non-inclusion criteria to chemoimmunotherapy arm:

- Any negative answer concerning the inclusion criteria of chemoimmunotherapy arm.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    phase induction-R-I

    R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years. Patients with insufficient metastatic response at the end of induction chemotherapy, defined as SIOPEN score \> 3 or less than 50% reduction in mIBG score (or \> 3 bone lesions or less 50% reduction in number of FDG-PET-avid bone lesions for mIBG-non avid tumours), have a poorer prognosis. Chemoimmunotherapy arm Metastatic response rate after 4 courses of irinotecan-temozolomide (TEMIRI) combined with dinutuximab beta (DB) in patients with insufficient metastatic response at the end of induction chemotherapy (TEMIRI/DB).

    Drug: Vincristine · Drug: Carboplatin · Drug: Etoposide · Drug: Vindesine · Drug: Dacarbazine · Drug: Ifosfamide · Drug: Doxorubicin · Drug: Dinutuximab Beta · Drug: Cisplatin · Drug: Temozolomide 100 MG · Drug: Irinotecan · Drug: Cyclophosphamid

  • Experimental
    Phase high dose chemotherapy consolidation

    R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).

    Drug: Busulfan · Drug: Melphalan · Drug: Thiotepa

  • Experimental
    Phase of radiotherapy

    R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease

    Radiation: Radiotherapy · Drug: Dinutuximab Beta

Interventions

  • 1.5 mg/m2 (max dose 2 mg)

    Also known as: L01CA02

  • 750 mg/m2

    Also known as: LO1XA02

  • 175 mg/m2

    Also known as: L01CB01

  • 3 mg/m2/day (max dose 6 mg)

    Also known as: L01CA03

  • 200 mg/m2/day

    Also known as: L01AX04

  • 1500 mg/m2/day

  • 30 mg/m2/dose

    Also known as: L01DB01

  • \< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses

    Also known as: L01AB01

  • 140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose

    Also known as: L01AA03

  • 300 mg/m2/day over 2 hours

    Also known as: L01AC01

  • RadiationRadiotherapy

    21.6 Gy 21.6 Gy + boost de 14.4 Gy

  • DrugDinutuximabStudies of DinutuximabDinutuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day

    Also known as: L01XC16

  • 80 mg/m2/24h

    Also known as: L01XA01

  • DrugTemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 mg/m²/Day

  • 50 mg/m²/jour de J0 à J4

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.

06

What researchers measure

Primary outcomes

  1. Event free survival (EFS)

    Event free survival

    Time frame: Assessed at each end of randomization sequences up to one year

07

Study locations

106 of 142 sites recruiting

Showing the first 100 of 142 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Nov 2026, 84 months after the start.

Of 20 phase 3 interventional studies under Neuroblastoma, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 80 and three quarters within 122. This study's planned 84 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2020
First posted
Jan 9, 2020
StartActual
Nov 5, 2019
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2032
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04221035
Responsible party
Sponsor
First posted
Jan 9, 2020
Start date
Nov 5, 2019
Primary completion
Nov 2026 (estimated)
Completion
Nov 2032 (estimated)
Last update
Jun 26, 2025

Study contacts

Claudia Pasqualini, MD PhD
Contact
claudia.pasqualini@gustaveroussy.fr
+33 (0)1 42 11 42 11
Habiba Attalah, PhD
Contact
habiba.attalah@gustaveroussy.fr
+33 (0)1 42 11 64 46
Claudia Pasqualini, MD PhD
study chair · Gustave roussy, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vincristine · Carboplatin · Etoposide · Vindesine · Dacarbazine · Ifosfamide · Doxorubicin · Busulfan · Melphalan · Thiotepa · Dinutuximab · Cisplatin · Temozolomide · Irinotecan · Cyclophosphamide

Start the discussion